Financial Assistance for Patients with CLL & SLL

Financial Assistance for Patients with Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL)The Leukemia & Lymphoma Society's Co-Pay Assistance Program provides eligible CLL and SLL patients up to $4,500 annually for treatment-related expenses.We can help pay for:

• Medical insurance premiums
• Treatment-related co-pays, deductibles, and co-insurance (for expenses covered by the program)
• Co-pays for prescription medication related to prescribed treatment
• Co-pays for labs, scans, and tests as follow-up care after being diagnosed.

Healthcare professionals may apply on behalf of a patient.Based upon historical and recent trends, we anticipate the CLL Co-Pay fund will be open through the winter of 2025.For a full list of covered expenses, visit our website at www.LLS.org/copay .  LEARN MORE AND APPLY  Questions?

• Visit: www.LLS.org/copay (for English) or www.LLS.org/copagos (for Spanish)
• Email:  
• Call: (877) 557-2672

Sincerely,The Patient Financial Assistance Team

Hi Monica,
I use LLC a great deal. They are very responsive and communicate well with patients. 

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) treatments often come with financial challenges, especially when balancing medical costs with academic responsibilities. While managing both can feel overwhelming, students dealing with such situations may find it helpful to focus on steady academic progress. In particular, MyAssignmenthelp offers assistance for students dealing with complex academic subjects. If you're struggling with financial accounting tasks, financial accounting assignment help <!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}--> myassignmenthelp.com/financial_accounting_assignment_help.html through MyAssignmenthelp can ease the academic pressure during such a difficult time. Maintaining coursework alongside medical or personal responsibilities is never easy, and staying organized with academic deadlines becomes even more critical.